Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00088926" target="_blank" >RIV/00216224:14110/16:00088926 - isvavai.cz</a>

Výsledek na webu

<a href="http://paperity.org/p/76277811/esgar-2016-book-of-abstracts" target="_blank" >http://paperity.org/p/76277811/esgar-2016-book-of-abstracts</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13244-016-0502-9" target="_blank" >10.1007/s13244-016-0502-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

Popis výsledku v původním jazyce

Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.

Název v anglickém jazyce

Endoluminal radiofrequency ablation of hilarcholangiocarcinoma

Popis výsledku anglicky

Purpose: To prove efficacy of endoluminal radiofrequency ablation in palliative treatment of hilar cholangiocarcinoma. Material and methods: 35 patients with hilar cholangiocarcinoma have been enrolled in a prospective randomised study since 2010. The infiltrative type of cholangiocarcinoma was predominant. 65 non-covered self-expandable metal stents were inserted. In group A (n=18) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB; EMcision Ltd., London, UK) was performed 0-48 hours prior to the stent insertion, in group B (n=17) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meier analysis). Results: The rate of biochemical pancreatitis, which was resolved in 3 days after stent insertion, was significantly higher in group A. The average primary stent patency was 5.9 and 5.

Druh

O - Ostatní výsledky

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

<a href="/cs/project/NV15-32484A" target="_blank" >NV15-32484A: Využití nových biotechnologií v prevenci a léčbě stenóz žlučových cest</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů